RSI Overbought Stocks
DNTH is RSI overbought, meaning strong buying pressure may lead to a short-term consolidation or pullback.
DIANTHUS THERAPEUTICS INC (DNTH) Stock Price & Overview
NASDAQ:DNTH • US2528281080
Current stock price
86 USD
+1.44 (+1.7%)
At close:
86 USD
0 (0%)
After Hours:
The current stock price of DNTH is 86 USD. Today DNTH is up by 1.7%. In the past month the price increased by 40%. In the past year, price increased by 433.5%.
DNTH Key Statistics
52-Week Range13.365 - 88.493
Current DNTH stock price positioned within its 52-week range.
1-Month Range60.16 - 88.493
Current DNTH stock price positioned within its 1-month range.
- Market Cap
- 4.445B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -4.10
- Dividend Yield
- N/A
DNTH Stock Performance
Today
+1.7%
1 Week
+4.31%
1 Month
+40.00%
3 Months
+116.73%
Longer-term
6 Months +146.14%
1 Year +433.50%
2 Years +302.81%
3 Years N/A
5 Years N/A
10 Years N/A
DNTH Stock Chart
DNTH Stock Screens
DNTH currently appears in the following ChartMill screener lists.
DNTH Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to DNTH. When comparing the yearly performance of all stocks, DNTH is one of the better performing stocks in the market, outperforming 99.17% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
DNTH Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to DNTH. DNTH has a great financial health rating, but its profitability evaluates not so good.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
DNTH Earnings
On March 9, 2026 DNTH reported an EPS of -1.43 and a revenue of 284.00K. The company missed EPS expectations (-30.33% surprise) and missed revenue expectations (-30.2% surprise).
Next Earnings DateMay 11, 2026
Last Earnings DateMar 9, 2026
PeriodQ4 / 2025
EPS Reported-$1.43
Revenue Reported284K
EPS Surprise -30.33%
Revenue Surprise -30.20%
DNTH Forecast & Estimates
21 analysts have analysed DNTH and the average price target is 130.48 USD. This implies a price increase of 51.72% is expected in the next year compared to the current price of 86.
For the next year, analysts expect an EPS growth of 6.65% and a revenue growth -38.11% for DNTH
Analysts
Analysts87.62
Price Target130.48 (51.72%)
EPS Next Y6.65%
Revenue Next Year-38.11%
DNTH Groups
Sector & Classification
DNTH Financial Highlights
Over the last trailing twelve months DNTH reported a non-GAAP Earnings per Share(EPS) of -4.1. The EPS decreased by -57.69% compared to the year before.
Income Statements
Revenue(TTM)2.04M
Net Income(TTM)-162.34M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.58% | ||
| ROE | -32.9% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%-76.54%
Sales Q2Q%-71.57%
EPS 1Y (TTM)-57.69%
Revenue 1Y (TTM)-67.35%
DNTH Ownership
Ownership
Inst Owners120.69%
Shares51.69M
Float50.10M
Ins Owners0.01%
Short Float %18.35%
Short Ratio8.36
DNTH Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About DNTH
Company Profile
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. The company is headquartered in New York City, New York and currently employs 92 full-time employees. The company went IPO on 2018-06-21. The firm is focused on developing complement therapeutics for patients living with severe autoimmune and inflammatory diseases. Its advanced product candidate, DNTH103, is a clinical-stage, highly potent, selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of C1s. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile designed to support less frequent, lower dose, self-administration as a convenient S.C. injection. The company is conducting three mid- to late-stage clinical trials with DNTH103 in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN).
Company Info
IPO: 2018-06-21
DIANTHUS THERAPEUTICS INC
7 Times Square, 43Rd Floor
New York City NEW YORK US
Employees: 92
Phone: 19299994055
DIANTHUS THERAPEUTICS INC / DNTH FAQ
Can you describe the business of DIANTHUS THERAPEUTICS INC?
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. The company is headquartered in New York City, New York and currently employs 92 full-time employees. The company went IPO on 2018-06-21. The firm is focused on developing complement therapeutics for patients living with severe autoimmune and inflammatory diseases. Its advanced product candidate, DNTH103, is a clinical-stage, highly potent, selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of C1s. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile designed to support less frequent, lower dose, self-administration as a convenient S.C. injection. The company is conducting three mid- to late-stage clinical trials with DNTH103 in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN).
What is the stock price of DIANTHUS THERAPEUTICS INC today?
The current stock price of DNTH is 86 USD. The price increased by 1.7% in the last trading session.
What is the dividend status of DIANTHUS THERAPEUTICS INC?
DNTH does not pay a dividend.
How is the ChartMill rating for DIANTHUS THERAPEUTICS INC?
DNTH has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the employee count for DNTH stock?
DIANTHUS THERAPEUTICS INC (DNTH) currently has 92 employees.
Can you provide the market cap for DIANTHUS THERAPEUTICS INC?
DIANTHUS THERAPEUTICS INC (DNTH) has a market capitalization of 4.45B USD. This makes DNTH a Mid Cap stock.
Can you provide the short interest for DNTH stock?
The outstanding short interest for DIANTHUS THERAPEUTICS INC (DNTH) is 18.35% of its float.